Should a patient on low-dose imipramine 25 mg nightly be tapered before stopping the medication?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Taper Imipramine 25mg Before Discontinuation

Even at the low dose of 25 mg nightly, imipramine should be tapered gradually rather than abruptly discontinued to avoid withdrawal symptoms and rebound worsening of the underlying condition. 1

Why Tapering is Necessary

The FDA label explicitly states that "Dosage should be tapered off gradually rather than abruptly discontinued" 1. This recommendation applies regardless of dose, as the guideline literature emphasizes that "prescribers are generally encouraged to taper medication slowly to avoid withdrawal symptoms" and "rebound worsening of symptoms" 2.

While 25 mg is indeed a low dose (the FDA label lists this as the starting dose for childhood enuresis), tricyclic antidepressants like imipramine carry particular risks when stopped abruptly:

  • Withdrawal symptoms can emerge even from low doses
  • Rebound symptoms of the underlying condition may occur weeks to months after the last dose 2
  • The anticholinergic and cardiovascular effects of tricyclics make gradual discontinuation prudent

Practical Tapering Approach

For a patient on 25 mg nightly:

Recommended taper schedule:

  • Reduce to 12.5 mg nightly for 1-2 weeks
  • Then reduce to 12.5 mg every other night for 1 week
  • Then discontinue

If the patient has been on this dose for an extended period (>6 months) or has risk factors (previous failed discontinuation attempts, anxiety sensitivity, longer duration of use), consider an even slower taper over 4-6 weeks with smaller decrements 3, 4.

Monitoring Plan

Critical aspects of safe discontinuation include:

  • Monitor for 2-3 months after the last dose, as mood and anxiety symptoms may not return immediately 2
  • Watch for withdrawal symptoms: anxiety, agitation, insomnia, irritability, restlessness 1
  • Distinguish between withdrawal (typically peaks within 1-2 weeks and resolves) versus relapse (gradual onset, persistent)
  • Consider daily observation by family members during the taper 1

Common Pitfalls to Avoid

  • Don't assume low dose = no taper needed: The FDA label makes no dose exception for tapering requirements 1
  • Don't discontinue in unstable settings: Avoid starting a taper during life stressors or transitions in care 2
  • Don't confuse withdrawal with relapse: If symptoms emerge during taper, pause or slow the taper rather than immediately assuming treatment failure 3, 5

The evidence consistently supports gradual tapering as standard practice for all antidepressants including tricyclics, with the understanding that abrupt discontinuation poses unnecessary risk even at low doses 2, 1, 3.

References

Guideline

practice parameter on the use of psychotropic medication in children and adolescents.

Journal of the American Academy of Child and Adolescent Psychiatry, 2009

Research

Stopping antidepressants: when and how.

Australian prescriber, 2026

Research

Outcomes of hyperbolic tapering of antidepressants.

Therapeutic advances in psychopharmacology, 2023

Research

Stopping antidepressants safely.

African journal of primary health care & family medicine, 2026

Related Questions

How should a patient who has been taking 25 mg dothiepin (dosulepin) for 5 years be tapered off the medication?
What is the recommended tapering schedule for amitriptyline?
Should a 50-year-old patient who has been taking duloxetine (Cymbalta) 30 mg daily for one month be tapered before discontinuation?
What is the recommended tapering schedule for reducing citalopram from 20 mg to a lower dose?
What is the recommended method for tapering and discontinuing bupropion (including extended‑release and immediate‑release formulations)?
For a patient with end‑stage renal disease on chronic dialysis presenting with acute coronary syndrome, can ticagrelor be used and what is the appropriate dosing regimen?
What are the recommended guidelines for initiating and titrating oral hypoglycemic agents—including metformin, sulfonylureas, sodium‑glucose cotransporter‑2 (SGLT2) inhibitors, dipeptidyl peptidase‑4 (DPP‑4) inhibitors, and thiazolidinediones—in adults with type 2 diabetes, taking into account renal function, liver disease, and hypoglycemia risk?
In a 45-year-old man diagnosed with nephrotic syndrome, which findings would you expect: proteinuria exceeding 3.5 grams per day, hypoalbuminemia, hyperlipidemia, increased risk of infections, or all of the above?
Can a 1‑year‑old child use Flomist (fluticasone nasal spray)?
In a 2½‑year‑old girl with recent fever, decreasing leukocytosis and C‑reactive protein, a positive nasopharyngeal adenovirus PCR, and currently stable on intravenous amoxicillin, is further hospitalization required or can she be safely discharged on oral amoxicillin if she remains well‑appearing?
How should obesity be managed in adults with BMI ≥30 kg/m² or BMI 27 kg/m² with hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnea?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.